Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: Is it helpful?

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 2, 2012, Pages 149-161

  Abrams, Ross A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adjuvant chemotherapy; adjuvant radiotherapy; pancreatic adenocarcinoma

Indexed keywords

ALPHA INTERFERON; CA 19-9 ANTIGEN; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; SMAD4 PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEALTH CARE NEED; HUMAN; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PATIENT CARE; PROTEIN EXPRESSION; REVIEW; SUPERIOR MESENTERIC ARTERY; SYSTEMIC THERAPY;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; EVIDENCE-BASED MEDICINE; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84858031453     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.3     Document Type: Review

References (76)

1. Shapiro TM. Adenocarcinoma of the pancreas: A statistical analysis of biliary bypass vs Whipple resection in good risk patients. Ann. Surg. 182(6), 715-721 (1975).
2. Fitzgerald PJ. Pancreatic cancer. The dismal disease. Arch. Pathol. Lab. Med. 100(10), 513-515 (1976).
3. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 resections without an operative mortality. Ann. Surg. 211(4), 447-458 (1990). (Pubitemid 20138186)
4. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann. Surg. 217(5), 430-435 (1993).
5. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 165(1), 68-72 (1993).
6. Spencer MP, Sarr MG, Nagorney DM. Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified? Ann. Surg. 212(2), 140-143 (1990). (Pubitemid 20241037)
7. Abrams RA, Grochow LB. Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg. Clin. North Am. 75(5), 925-938 (1995).
8. Klimstra DS, Pitman, MB, Hruban RH. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch. Pathol. Lab. Med. 133, 454-464 (2009).
9. Hruban RH, Adsay NV. Molecular Classification of neoplasms of the pancreas. Hum. Pathol. 40, 612-623 (2009).
10. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann. Surg. 223(5), 506-511; discussion 511-512 (1996).
11. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4(6), 567-579 (2000).
12. Yeo CJ, Cameron JL, Sohn TA et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann. Surg. 226(3), 248-257 (1997).
13. Riall TS, Cameron JL, Lillemoe KD et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 140(5), 764-772 (2006). (Pubitemid 44648193)
14. Berger DS, Fletcher GH, Lindberg RD, Jesse RH Jr. Elective irradiation of the neck lymphatics for squamous cell carcinomas of the nasopharynx and oropharynx. Am. J. Roentgenol. Radium Ther. Nucl. Med. 111(1), 66-72 (1971).
15. Brady LW, Fletcher GH, Levitt SH. Cancer of the breast. The role of radiation therapy after mastectomy. Cancer. 39(SUPPL6), 2868-2874 (1977). (Pubitemid 8130401)
16. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann. Surg. 168(3), 337-356 (1968).
17. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352-358 (1990). (Pubitemid 20042739)
18. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337(14), 956-962 (1997). (Pubitemid 27425951)
19. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 337(14), 949-955 (1997). (Pubitemid 27425950)
20. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. European Organization for Research and Treatment of Cancer Trial 2293. N. Engl. J. Med. 350(19), 1945-1952 (2004). (Pubitemid 38580197)
21. Cooper JS, Pajak TF, Forastiere AA et al. Intergroup postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937-1944 (2004).
22. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma N. Engl. J. Med. 324, 709-715 (1991).
23. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312(23), 1465-1472 (1985).
24. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J. Clin. Oncol. 25(26), 4110-4117 (2007). (Pubitemid 47492955)
25. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
26. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 339(1), 21-26 (1998). (Pubitemid 28304493)
27. Fermé C, Eghbali H, Meerwaldt JH et al. EORTC-GELA H8 trial chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N. Engl. J. Med. 357(19), 1916-1927 (2007). (Pubitemid 350074687)
28. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28(13), 2181-2190 (2010).
29. Pignon JP, Arriagada R, Ihde DC et al. Meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327(23), 1618-1624 (1992).
30. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Eng. J. Med. 324, 1685-1690 (1991).
31. Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21(1), 92-98 (2003).
32. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl Cancer Inst. 80(10), 751-755 (1988).
33. Loehrer PJ Sr, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An eastern cooperative oncology group trial. J. Clin. Oncol. 29(31), 4105-4112 (2011).
34. Abrams RA. Comment on Adjuvant therapy in pancreatic cancer: A critical appraisal. Drugs 67(17), 2481-2485 (2007). (Pubitemid 350159161)
35. Kalser MH, Ellenberg SS. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120, 899-903 (1985). (Pubitemid 15040883)
36. Yeo CJ, Abrams RA, Grochow LB et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. Ann. Surg. 225, 621-633 (1997).
37. Herman JM, Swartz MJ, Hsu CC et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J. Clin. Oncol. 26(21), 3503-3510 (2008).
38. Corsini MM, Miller RC, Haddock MG et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J. Clin. Oncol. 26(21), 3511-3516 (2008).
39. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann. Surg. 230, 776-782 (1999).
40. Neoptolemos JP, Stocken DD, Friess H et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomized controlled trial. Lancet 358, 1576-1585 (2001). (Pubitemid 33101907)
41. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200-1210 (2004). (Pubitemid 38339364)
42. Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjutant therapy of pancreatic cancer. Lancet 358, 1565-1566 (2001). (Pubitemid 33101899)
43. Hsu CC, Herman JM, Corsini MM et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann. Surg. Oncol. 17, 981-990 (2010).
44. Tepper J, Nardi G, Suit H. Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 37, 1519-1524 (1976).
45. Griffin JF, Smalley SR, Jewell W et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66, 56-61 (1990). (Pubitemid 20197085)
46. Chakravarthy A, Abrams RA. Radiation therapy and 5-fluorouracil in pancreatic cancer. Semin. Radiat. Oncol. 7(4), 1-9 (1997).
47. Regine WF, Winter KA, Abrams R et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 Phase III trial. Ann. Surg. Oncol. 18(5), 1319-1326 (2011).
48. Abrams RA, Winter KA, Regine WF et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A Phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 809-816 (2012).
49. Showalter TN, Winter KA, Berger AC et al. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pan 187-198 on creatic cancer: A secondary analysis of RTOG 9704. Int. J. Radiat. Oncol. Biol. Phys. 81(5), 1328-1335 (2010).
50. Berger AC, Garcia M Jr, Hoffman JP et al. Postresection CA 19-19 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J. Clin. Oncol. 26(36), 5918-5922 (2008).
51. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative intent resection of pancreatic cancer: A multicenter randomized controlled trial. JAMA 297, 267-277 (2007). (Pubitemid 46143304)
52. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304(10), 1073-1081 (2010).
53. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg. 185(5), 476-480 (2003). (Pubitemid 36513960)
54. Linehan DC, Tan MC, Strasberg SM et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution Phase II study. Ann. Surg. 248(2), 145-151 (2008).
55. Picozzi VJ, Abrams RA, Decker PA et al. American College of Surgeons Oncology Group multicenter Phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann. Oncol. 22(2), 348-354 (2011).
56. Märten A, Schmidt J, Ose J et al. A randomized multicentre Phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2. BMC Cancer 9, 160 (2009).
57. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann. Surg. 240, 293-298 (2004). (Pubitemid 38963021)
58. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). (Pubitemid 46972777)
59. Di Marco M, Di Cicilia R, Macchini M et al. Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? Oncol. Rep. 23(5), 1183-1192 (2010).
60. Xie DR, Yang Q, Chen DL et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J. Clin. Oncol. 40(5), 432-441 (2010).
61. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8, 82 (2008).
62. Fatima J, Schnelldorfer T, Barton J et al. Pancreatoduodenectomy for ductal adenocarcinoma: Implications of positive margin on survival. Arch. Surg. 145(2), 167-172 (2010).
63. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: The Leeds Pathology Protocol (LEEPP). HPB (Oxford) 11(1), 18-24 (2009).
64. Katz MHG, Wang H, Fleming JB et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann. Surg. Oncol. 16(4), 836-847 (2009).
65. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med. 7(4), e1000267 (2010).
66. Stratford JK, Bentrem DJ, Anderson JM et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 7(7), e1000307 (2010).
67. Ben-Josef E, Griffith K, Francis IR et al. Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J. Clin. Oncol. 27, 15s (2009).
68. Abelson JA, Murphy JD, Minn AY et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. doi:org/10.1016/j.ijrobp.2011.09.035 (2011) (Epub ahead of print).
69. Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(5), 1420-1426 (2010).
70. Mahadevan A, Jain S, Goldstein M et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(3), 735-742 (2010).
71. Kavanagh BD, Timmerman R, Meyer JL. The expanding roles of stereotactic body radiation therapy and oligofractionation: Toward a new practice of radiotherapy. Front. Radiat. Ther. Oncol. 43. 370-381 (2011).
72. Conroy T, Desseigne F Y, Chou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817-1825 (2011).
73. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 40(5), 644-652 (2011).
74. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: Molecular targeted therapies. Mt Sinai J. Med. 77(6), 606-619 (2010).
75. Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27(11), 1806-1813 (2009).
76. Abrams RA, Shah A. Chapter 46. In: Pancreatic Cancer, Clinical Radiation Oncology (3rd Edition). Gunderson LL, Tepper JE (Eds). Elsevier, Amsterdam, The Netherlands, 935-958 (2012).